PsychemedicsNASDAQ: PMD

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.

Psychemedics is in the Healthcare sector

Psychemedics is in the Diagnostics & Research industry

Psychemedics is headquartered in United States

Psychemedics initial public offering (IPO) was on 22 January 1987

https://www.psychemedics.com

No, Psychemedics is not included in the S&P 500 index

No, Psychemedics is not included in the NASDAQ 100 index

No, Psychemedics is not included in the Dow Jones index